PAMA 2026: What the Latest Delay of Lab Test Payment Cuts Means for Diagnostics Companies

For the seventh time since 2019, Congress has pushed back the Medicare payment cuts that the Protecting Access to Medicare Act was supposed to deliver. The Consolidated Appropriations Act, 2026, signed on 3 February 2026, froze Clinical Laboratory Fee Schedule rates through the end of this year and reset the private-payer data reporting cycle.

If you sell a diagnostic test in the United States, this is not a reprieve you can file away. The reporting period that just closed is the one that sets your rates for the next three years.

What PAMA was meant to do

Section 216 of PAMA, enacted in 2014, rebuilt how Medicare pays for clinical diagnostic laboratory tests. Instead of legacy fee schedule amounts inherited from the 1980s, rates would be set at the weighted median of what private payers actually pay, reported by laboratories themselves. The first collection ran in 2016 and the first market-based rates took effect in 2018.

The result was a steep downward reset, so Congress built in a phase-in cap and then, repeatedly, delayed the whole thing. Each delay has followed the same shape: freeze the rates for another year, push the next reporting period back, and leave the underlying methodology untouched.

What actually changed this year

Section 6226 of the CAA 2026 did three things.

It froze CLFS rates for 2026, so there is no phase-in reduction this calendar year.

It moved the data collection window to 1 January through 30 June 2025, and the reporting window to 1 May through 31 July 2026. That period has now closed. Reporting entities filed private-payer payment data at the taxpayer identification number level for their applicable laboratories.

It set the next phase-in ceiling. Beginning 1 January 2027 and running through 2029, payment for a test may not be reduced by more than 15 percent per year against the prior year amount.

That last point is the one to underline. The cuts have not been cancelled. They have been scheduled. The data submitted by 31 July 2026 becomes the basis for rates that begin on 1 January 2027, and the 15 percent annual floor means a test facing a large gap between its current rate and its market-based median will now walk down over three consecutive years rather than falling in one step.

Why the freeze is not good news for everyone

A rate freeze sounds like stability, and for incumbent test volumes it is. But two effects cut the other way.

The first is compression. Laboratories have absorbed several years of cost inflation — labour, reagents, instrumentation, courier logistics — against frozen Medicare rates. A freeze in nominal terms is a real-terms cut, and it lands hardest on hospital outreach labs and independent regional labs operating on thin margins.

The second is the data quality problem. Rates for 2027 to 2029 are calculated from what laboratories reported this summer. Historical reporting has skewed toward large national laboratories, whose negotiated private-payer rates tend to be lower than those secured by hospital-based and regional labs. If the same skew persists in the 2026 submission, the resulting weighted medians will sit below what a representative market would produce, and every lab will be paid against them. Industry groups have been pressing for structural reform through the RESULTS Act precisely because each delay preserves the methodology that produces the skew.

What it means if you are a diagnostics company

You are affected whether or not you operate a laboratory yourself, because the rate your customers receive determines what they will pay you.

If your test has an existing CLFS code, model the 2027 rate now rather than waiting for the November fee schedule release. Take the current rate, apply the 15 percent annual reduction ceiling for three consecutive years, and treat that as the downside case for your pricing and gross margin. If your revenue model only works at today's rate, you have eighteen months to change something.

If your test is new, the more consequential question is how it is priced in the first place. New codes are priced by crosswalk to an existing test or by gapfill through Medicare administrative contractors, and that initial determination anchors everything that follows. Advanced diagnostic laboratory tests sit under a separate set of rules with their own reporting obligations and an initial period priced at actual list charge. Which bucket you land in is a strategic decision, not an administrative one, and it should be made alongside your FDA pathway decision rather than after it.

If your test is algorithm-driven, note that the boundary between the lab fee schedule and the outpatient system is moving. CMS proposed shifting a set of laboratory algorithm codes off the CLFS in its CY2027 outpatient rule, which we covered in the Software as a Medical Service piece. Two payment systems with different rate-setting logic are now competing for the same products.

Three things to do before January

Confirm your reporting obligations. If any entity in your corporate structure meets the applicable laboratory definition, the next collection and reporting cycle will come around, and the penalties for non-reporting are real. CMS maintains a detailed FAQ on who must report and what counts as applicable information.

Build the downside model. Three years of 15 percent step-downs compounds to roughly a 39 percent reduction against today's rate. Run your unit economics at that number and see what breaks.

Diversify the payer mix and the geography. Medicare rate exposure is a concentration risk, and several European systems set diagnostic and digital health payment through entirely different mechanisms — compared side by side in our international reimbursement pathways article. If Europe is in scope, the EU MDR and UKCA guide and the market access guide are the places to start.

Closing

Seven delays in seven years is not a policy. It is a signal that the underlying methodology has never commanded enough confidence to survive contact with the market it was built to measure. Plan on the cuts arriving in 2027, because this time there is a submitted data set behind them and a defined three-year schedule.

MedTech Compass scores markets on regulatory and payment friendliness together, and DevicePath helps map classification and pathway questions.

This article is general strategic awareness, not legal, coding or reimbursement advice. Confirm current CLFS rules and rates before relying on them.

Sources

CLFS and PAMA Reporting and Resources, Centers for Medicare and Medicaid Services

Clinical Laboratory Fee Schedule: PAMA Reporting Frequently Asked Questions, Centers for Medicare and Medicaid Services

A Band-Aid on PAMA: Appropriation Bill Delays Cuts and Reporting Period, Bass, Berry and Sims

PAMA laboratory data reporting requirements for hospitals, Healthcare Financial Management Association

PAMA Delay Included in New Spending Law, Laboratory Economics

Hospital Outpatient Prospective Payment System, Centers for Medicare and Medicaid Services